Summary of Significant Accounting Policies - Additional Information (Details) (USD $)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 69 Months Ended 78 Months Ended 12 Months Ended 9 Months Ended 12 Months Ended 9 Months Ended 12 Months Ended 9 Months Ended
Dec. 31, 2007
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2011
Sep. 30, 2012
Dec. 23, 2010
Jul. 13, 2007
Dec. 31, 2011
Federal Deposit Insurance Corporation [Member]
Dec. 31, 2010
Federal Deposit Insurance Corporation [Member]
Dec. 31, 2011
Securities Investor Protection Corporation [Member]
Cash [Member]
Dec. 31, 2011
Securities Investor Protection Corporation [Member]
Per Customer [Member]
Mar. 28, 2012
Convertible Promissory Note [Member]
Aug. 31, 2007
Convertible Promissory Note [Member]
Jul. 13, 2007
Accredited Investors [Member]
Jul. 13, 2007
Chief Financial Officer [Member]
Sep. 30, 2012
Stock Option
Sep. 30, 2011
Stock Option
Dec. 31, 2011
Stock Option
Dec. 31, 2010
Stock Option
Sep. 30, 2012
Warrants
Sep. 30, 2011
Warrants
Dec. 31, 2011
Warrants
Dec. 31, 2010
Warrants
Sep. 30, 2012
Convertible Notes Payable
Sep. 30, 2012
Fulton Project
Sep. 30, 2012
Lancaster Biorefinery
Minimum
Sep. 30, 2012
Lancaster Biorefinery
Maximum
Significant Accounting Policies [Line Items]                                                              
Proceeds from sale of stock through private placement $ 14,500,000     $ 0    $ 0 $ 0 $ 544,500 $ 544,500                                            
Working capital deficit   2,379,000   2,379,000   1,520,000   1,520,000 2,379,000                                            
Estimated operating expenses for the next 12 months       1,700,000                                                      
Number of months in which current resources as well as the resources available in the short term will be sufficient       1 month                                                      
Ownership interest in BlueFire Fulton Renewable Energy LLC sold                   1.00%                                          
Research and development expenses   129,000 158,000 420,000 429,000       14,883,000                                            
Antidilutive securities excluded from computation of earnings per share                                       1,229,659 3,287,159 1,229,659 3,287,159 6,891,534 6,886,694 7,115,275 6,886,694 2,502,000 300,000,000 100,000,000 125,000,000
Convertible Debt                               300,000 2,000,000 500,000 25,000                        
Proceeds from issuance of common stock 15,500,000     35,000 250,000 350,000    14,710,000 14,745,000                                            
Percentage Of Tax Benefit Realized Upon Settlement           50.00%                                                  
Number Of Accredited Investors                     0             0                          
Cash, FDIC Insured Amount                       $ 250,000 $ 100,000 $ 500,000 $ 100,000                                
Cash Insured Repayment Period                       Jan. 01, 2014                                      
Percentage Of Billed and Unbilled Grant Revenues           100.00% 100.00%                                                
Percentage Of Accounts Payable           63.00% 39.00%